Real-World Effectiveness of Belimumab in Patients with Active Lupus
Journal of Clinical Medicine · 11.12.2023 · 12 (24) · 7627
DOI: 10.3390/jcm12247627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.12.2023. Verfasst von Yuya Sumichika und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Japan Grant-in-Aid for Scientific Research, Japan Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
This study evaluated the real-world effectiveness of belimumab (BLM) in the treatment of systemic lupus erythematosus (SLE) patients with moderate to high disease activity. This retrospective cohort study enrolled 129 Japanese patients with moderate to high SLE disease activity who received BLM between January 2013 and March 2023. The clinical outcomes, including the flare-free survival, SLE Disease Activity Index 2000 (SLEDAI-2K) score, and prednisone-equivalent dose, in the BLM and mycophenolate mofetil (MMF) treatment groups were compared before and after treatment. Safety data for BLM were collected. Additionally, we compared the effectiveness of BLM and intravenous cyclophosphamide (IV-CY) treatment using the stabilized inverse probability of treatment weighting (IPTW) method based on the propensity scores. This observational study enrolled 129 patients with moderate/severe SLE: 48 patients received belimumab, 45 received IV-CY, and 36 received MMF and prednisolone for remission induction therapy. The median follow-up for the BLM group was 17.0 months. Among them, 19 received BLM plus MMF. BLM significantly reduced the mean SLEDAI-2K (from mean baseline to 52 weeks: 49.2% reduction from 12.8 to 6.5) and prednisone daily dose (from mean baseline to 52 weeks: 21.9% reduction from 12.8 to 10.0 mg/day). The flare-free survival at 52 weeks was not significantly different between the BLM and MMF groups. There was no significant difference in the flare-free survival rates or reduction rates of the SLEDAI-2K between the patients treated with BLM and those treated with BLM plus MMF. In the propensity score-matched comparative analyses, there was no significant difference in the flare-free survival rates or an estimated decline in the SLEDAI-2K scores between the patients with lupus treated with BLM and IV-CY. BLM may be a promising alternative treatment option for lupus patients with moderate or high disease activity who do not respond to conventional treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
- Department of Rheumatology, Ohta Nishinouchi General Hospital Foundation, 2-5-20 Nishinouchi, Koriyama 963-8558, Fukushima, Japan.
ORCID-Profile: Shuhei Yoshida, Eiji Suzuki, Yuya Fujita, Shuzo Sato
Förderung
- the Japan Grant-in-Aid for Scientific Research
- Japan Grant-in-Aid for Scientific Research
Zitieren
APA
Sumichika, Y., Yoshida, S., Suzuki, E., Saito, K., Matsumoto, H., Temmoku, J., Fujita, Y., Matsuoka, N., Asano, T., Sato, S., & Migita, K. (2023). Real-World Effectiveness of Belimumab in Patients with Active Lupus. Journal of Clinical Medicine, 12(24), 7627. https://doi.org/10.3390/jcm12247627
Vancouver
Sumichika Y, Yoshida S, Suzuki E, Saito K, Matsumoto H, Temmoku J, et al. Real-World Effectiveness of Belimumab in Patients with Active Lupus. Journal of Clinical Medicine. 2023;12(24):7627. doi:10.3390/jcm12247627
BibTeX
@article{Sumichika2023,
author = {Sumichika, Yuya and Yoshida, Shuhei and Suzuki, Eiji and Saito, Kenji and Matsumoto, Haruki and Temmoku, Jumpei and Fujita, Yuya and Matsuoka, Naoki and Asano, Tomoyuki and Sato, Shuzo and Migita, Kiyoshi},
title = {Real-World Effectiveness of Belimumab in Patients with Active Lupus},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {24},
pages = {7627},
doi = {10.3390/jcm12247627}
}
EUVIMED